Minimal complications during cervical ripening
Non-pharma mode of action brings predictability to cervical ripening and allows efficient scheduling on the labour ward
Regular CTG monitoring not required
Midwifes insertion possible
Reduction is staff time requirement by 2.4 hours vs dinoprostone
DILAPAN-S achieves reliable first round cervical ripening success
Vaginal delivery rate comparable to prostaglandins
Vaginal delivery date within 24 hours comparable to low-dose oral misoprostol
The use of DILAPAN-S ensures comparable efficacy to pharmacological methods while may reduce staff time requirement.
DILAPAN-S minimizes the risk of uterine tachysystole during cervical ripening
No serious adverse maternal and neonatal outcomes
RCT DILAFOL, Saad 2019
* During cervical ripening interval
** Related to device used
Decrease need of analgesics
Across clinical trials comparing DILAPAN-S with dinoprostone, misoprostol and Foley catheter, more women in the DILAPAN-S group reported:
RCT SOLVE, Gupta 2022
Consistent Bishop score gain across all types of induced women
Solution for out-patient ripening procedure
Several clinical trials evaluated DILAPAN-S as effective and safe in labour induction of women with previous caesarean section.
Efficient and gentle cervical ripening suitable for almost all induced women.